Standout Papers

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic ste... 2022 2026 2023 2024144
  1. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (2022)
    Naim Alkhouri, Robert Herring et al. Journal of Hepatology

Immediate Impact

3 by Nobel laureates 59 standout
Sub-graph 1 of 21

Citing Papers

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
2025 Standout
NAFLD and NASH: etiology, targets and emerging therapies
2024 Standout
1 intermediate paper

Works of Robert Herring being referenced

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
2022 Standout

Author Peers

Author Last Decade Papers Cites
Robert Herring 364 252 66 98 23 482
Hiromi Kan 309 269 76 86 32 448
K. Shiva Kumar 319 173 83 130 22 444
Radhika P. Tampi 324 164 61 133 14 415
Yuta Wakui 276 199 40 47 22 452
Hong‐Lei Ma 344 146 78 113 27 437
Lucia Parlati 291 205 77 61 35 419
Jimmy Che‐To Lai 416 320 43 112 48 540
Roberta Forlano 351 148 91 96 37 542
Martin Coenen 245 213 40 32 17 488
Tsutomu Tamai 263 167 56 93 37 494

All Works

Loading papers...

Rankless by CCL
2026